Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18596217 | ANTI-INFLUENZA NEURAMINIDASE MONOCLONAL ANTIBODIES AND USES THEREOF | March 2024 | May 2025 | Allow | 15 | 2 | 1 | No | No |
| 18351374 | MATERIALS AND METHODS FOR PERFORMING HISTOCHEMICAL ASSAYS FOR HUMAN PRO-EPIREGULIN AND AMPHIREGULIN | July 2023 | May 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18192226 | COMPOSITIONS AND METHODS FOR TREATING SOLID TUMORS | March 2023 | April 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18182682 | Fusion Proteins Having a Toxin and Cancer Marker, Nanoparticles, and Uses Related Thereto | March 2023 | June 2025 | Allow | 27 | 1 | 0 | No | No |
| 18181802 | METHOD FOR IDENTIFYING NEOANTIGENS ON CANCER CELLS BY USING XENOANTIBODIES | March 2023 | June 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18164444 | Binding Proteins 1 | February 2023 | January 2025 | Allow | 24 | 1 | 0 | No | No |
| 17936398 | USE OF LENVATINIB PLUS ANTI-PD-1 MONOCLONAL ANTIBODY IN PREPARATION OF ANTI-HEPATOMA DRUG | September 2022 | March 2025 | Abandon | 30 | 1 | 1 | No | No |
| 17878533 | ANTI-TUMOUR RESPONSE TO MODIFIED SELF-EPITOPES | August 2022 | November 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17830027 | REDUCING BLOOD GLUCOSE, INSULIN RESISTANCE, OR HYPERLIPIDEMIA THROUGH RLIP76 PARTIAL DEPLETION | June 2022 | March 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17826948 | AUTOANTIBODY BIOMARKERS OF OVARIAN CANCER | May 2022 | December 2024 | Allow | 31 | 1 | 0 | No | No |
| 17750341 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS | May 2022 | June 2025 | Allow | 37 | 2 | 1 | Yes | No |
| 17717985 | METHODS OF DETECTING CANCER | April 2022 | January 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17706905 | METHODS OF PROGNOSIS | March 2022 | February 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17692787 | HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS | March 2022 | January 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17544852 | TRIPLE COMBINATION ANTIBODY THERAPIES | December 2021 | April 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17530974 | ANTIBODIES AND USE THEREOF | November 2021 | February 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17455192 | Bispecific Antibodies for use in treatment of NLRC4-GOF inflammasomapathy | November 2021 | April 2025 | Allow | 41 | 2 | 1 | No | Yes |
| 17527011 | NUCLEOBASE EDITORS AND USES THEREOF | November 2021 | February 2025 | Allow | 39 | 2 | 1 | No | No |
| 17609359 | DOSAGE REGIMENS FOR A COMBINATION OF ANTI-DR5 ANTIBODIES FOR USE IN TREATING CANCER | November 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17514454 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES | October 2021 | October 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17604356 | PEPTIDES IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR USE IN TREATMENT OF CANCER | October 2021 | June 2025 | Abandon | 44 | 5 | 0 | No | No |
| 17398846 | METHODS FOR THE DETECTION AND QUANTIFICATION OF CIRCULATING ENDOTHELIAL CELLS | August 2021 | March 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17354555 | T CELL RECEPTORS WITH IMPROVED PAIRING | June 2021 | January 2025 | Allow | 43 | 2 | 1 | No | No |
| 17416198 | PHOSPHORYLATED DICER ANTIBODY AND METHODS OF USE THEREOF | June 2021 | August 2024 | Allow | 38 | 1 | 1 | No | No |
| 17299038 | ANTI-IDO ANTIBODY AND USES THEREOF | June 2021 | July 2024 | Allow | 37 | 1 | 0 | No | No |
| 17222737 | PREVENTING, TREATING, AND REDUCING (PERSISTENT) POST-TRAUMATIC HEADACHE | April 2021 | October 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17196026 | ANTI-CD74 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODIES AND METHODS OF USING ANTI-CD74 ANTIBODIES | March 2021 | December 2024 | Abandon | 46 | 2 | 1 | No | No |
| 17191974 | METHODS FOR DIAGNOSING HEMATOLOGICAL CANCERS | March 2021 | December 2024 | Abandon | 45 | 2 | 1 | Yes | No |
| 17270924 | THERAPEUTIC AGENTS COMPRISING NUCLEIC ACIDS AND CAR-MODIFIED IMMUNE CELLS, AND USES THEREOF | February 2021 | February 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17147681 | Screening and Assessment of Potentially Malignant Oral Lesions | January 2021 | October 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 15734205 | BIOMARKERS, USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION, AND IMMUNOTHERAPY METHODS | December 2020 | February 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17052656 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASE OR DISORDER | November 2020 | January 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17050353 | HUMAN-DERIVED ANTI-(POLY-GA) DIPEPTIDE REPEAT (DPR) ANTIBODY | October 2020 | August 2024 | Allow | 45 | 2 | 0 | No | No |
| 17005051 | ANTI-CD73 ANTIBODIES | August 2020 | March 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 16964052 | SYSTEM AND METHOD FOR INDUCING CLUSTERS OF GENE REGULATORY PROTEINS TARGETED TO SPECIFIC GENOMIC LOCI | July 2020 | November 2024 | Abandon | 52 | 2 | 1 | No | No |
| 15733349 | METHODS OF DETECTION AND TREATMENT OF HYPER TRANSCRIPTION DISEASES | July 2020 | January 2025 | Abandon | 54 | 3 | 1 | No | No |
| 16956797 | Bispecific Antibody Construct Directed to MUC17 and CD3 | June 2020 | December 2024 | Allow | 54 | 3 | 1 | Yes | No |
| 16766845 | METHOD FOR REGULATING IN VITRO BIOSYNTHESIS ACTIVITY BY KNOCKING-OUT OF NUCLEASE SYSTEM | May 2020 | November 2024 | Abandon | 54 | 2 | 1 | No | No |
| 16753870 | DNA MONOCLONAL ANTIBODIES TARGETING CTLA-4 FOR THE TREATMENT AND PREVENTION OF CANCER | April 2020 | August 2024 | Allow | 53 | 3 | 1 | No | No |
| 16838651 | METHODS FOR DETECTING CIRCULATING TUMOR CELLS IN NON-SMALL CELL LUNG CANCER | April 2020 | May 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16813371 | FORMULATIONS FOR NEOPLASIA VACCINES | March 2020 | June 2025 | Abandon | 60 | 11 | 0 | No | No |
| 16688266 | USE OF MARKERS INCLUDING FILAMIN A IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | November 2019 | October 2024 | Abandon | 59 | 2 | 1 | No | Yes |
| 16025434 | NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME | July 2018 | March 2020 | Allow | 20 | 2 | 0 | No | No |
| 15835095 | NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME | December 2017 | August 2019 | Allow | 20 | 2 | 1 | Yes | No |
| 15507012 | INTERNALIZING MOIETIES FOR TREATMENT OF CANCER | February 2017 | July 2019 | Allow | 29 | 1 | 0 | No | No |
| 15241996 | NOVEL MHC CLASS II RESTRICTED T CELL EPITOPES FROM THE CANCER ANTIGEN, NY ESO-1 | August 2016 | November 2018 | Allow | 27 | 1 | 1 | No | No |
| 15228234 | PRAME DERIVED PEPTIDES AND IMMUNOGENIC COMPOSITIONS COMPRISING THESE | August 2016 | June 2019 | Allow | 34 | 2 | 0 | No | No |
| 15158146 | BIOMARKERS FOR GASTRIC CANCER AND USES THEREOF | May 2016 | February 2019 | Allow | 33 | 2 | 1 | Yes | No |
| 15099370 | HEPATIC ARTERIAL INFUSION OF CAR-T CELLS | April 2016 | July 2019 | Allow | 39 | 2 | 0 | No | No |
| 14890207 | BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF ENDOMETRIAL CANCER SUBJECTS TO LENVATINIB COMPOUNDS | November 2015 | November 2018 | Allow | 36 | 2 | 0 | No | No |
| 14724115 | MONOCLONAL ANTIBODIES FOR ENHANCING OR INHIBITING INSULIN-LIKE GROWTH FACTOR-I | May 2015 | September 2017 | Allow | 27 | 1 | 1 | No | No |
| 13688077 | BIOMARKERS FOR EARLY DETECTION OF OVARIAN CANCER | November 2012 | April 2015 | Allow | 28 | 3 | 1 | Yes | No |
| 13695062 | AUTOLOGOUS BIOLOGICAL CANCER VACCINE | October 2012 | February 2015 | Allow | 27 | 2 | 1 | No | No |
| 13637198 | HUMANIZED ANTI CXCR4 ANTIBODIES FOR THE TREATMENT OF CANCER | September 2012 | September 2015 | Allow | 36 | 2 | 1 | No | Yes |
| 13619576 | PROTEIN FORMULATION | September 2012 | November 2015 | Allow | 38 | 2 | 1 | No | Yes |
| 13586275 | IN VITRO TUMOR ANGIOGENESIS MODEL | August 2012 | June 2013 | Allow | 10 | 2 | 0 | No | No |
| 13569517 | Predictors for Cancer Treatment | August 2012 | May 2015 | Allow | 33 | 3 | 1 | No | No |
| 13566011 | Protein Involved in Ovarian Cancer | August 2012 | April 2015 | Allow | 33 | 1 | 1 | No | No |
| 13541296 | PLEXIN D1 AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY | July 2012 | April 2016 | Allow | 45 | 4 | 2 | Yes | No |
| 13474294 | Monoclonal Antibodies for Enhancing or Inhibiting Insulin-Like Growth Factor-I | May 2012 | February 2015 | Allow | 33 | 1 | 0 | No | No |
| 13427295 | THE TUMOR SUPPRESSOR KILLIN | March 2012 | May 2015 | Allow | 37 | 1 | 1 | No | No |
| 13324633 | ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND CANCER CELL MIGRATION | December 2011 | November 2015 | Allow | 47 | 4 | 1 | Yes | No |
| 13320558 | KITS FOR AND METHODS OF DIFFERENTIAL STAINING OF CERVICAL CANCER CELLS AND/OR TISSUES | November 2011 | June 2015 | Allow | 43 | 4 | 1 | No | No |
| 13287633 | MONOCLONAL ANTIBODY DS6, TUMOR-ASSOCIATED ANTIGEN CA6, AND METHODS OF USE THEREOF | November 2011 | January 2014 | Allow | 26 | 1 | 0 | Yes | No |
| 13252148 | ID-1 GENE AND GENE PRODUCTS AS THERAPEUTIC TARGETS FOR TREATMENT OF BREAST CANCER AND OTHER TYPES OF CARCINOMA | October 2011 | April 2014 | Allow | 31 | 2 | 1 | No | Yes |
| 13249148 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO COMBINATION THERAPY | September 2011 | September 2012 | Allow | 11 | 1 | 1 | No | No |
| 13134650 | NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCERS AND USES THEREOF | June 2011 | September 2012 | Allow | 15 | 1 | 0 | No | No |
| 13116319 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES | May 2011 | July 2013 | Allow | 25 | 2 | 0 | Yes | No |
| 13045293 | HUMAN MUTY | March 2011 | May 2012 | Allow | 14 | 2 | 0 | Yes | No |
| 13061770 | METHOD FOR DETERMINING THE ANTI-TUMOR EFFICACY OF MONOCLONAL ANTIBODIES | March 2011 | January 2016 | Allow | 58 | 3 | 0 | No | Yes |
| 13010005 | CHRONIC LYMPHOCYTIC LEUKEMIA PROGNOSIS AND TREATMENT | January 2011 | November 2014 | Allow | 46 | 1 | 0 | Yes | No |
| 12967273 | ANTI-CHEMOKINE AND ASSOCIATED RECEPTORS ANTIBODIES FOR INHIBITION OF GROWTH OF NEOPLASMS | December 2010 | October 2011 | Allow | 10 | 0 | 1 | No | No |
| 12676817 | METHODS FOR DIAGNOSING AND TREATING CANCERS | August 2010 | May 2015 | Allow | 60 | 3 | 2 | Yes | No |
| 12858964 | CANCER DETECTION METHODS AND TECHNIQUES | August 2010 | May 2013 | Allow | 33 | 1 | 0 | No | No |
| 12867449 | Anti-Adam-15 Antibodies and Utilization of the Same | August 2010 | February 2013 | Allow | 30 | 1 | 1 | No | No |
| 12865726 | METHOD FOR DETERMINATION OF SENSITIVITY TO ANTI-CANCER AGENT | August 2010 | March 2015 | Allow | 56 | 4 | 2 | Yes | No |
| 12814184 | GLYCOPROTEIN CANCER BIOMARKER | June 2010 | September 2013 | Allow | 39 | 2 | 1 | No | No |
| 12795142 | EPHA KINASE CANCER DIAGNOSTIC | June 2010 | July 2013 | Allow | 38 | 1 | 1 | No | No |
| 12763982 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 193P1E1B USEFUL IN TREATMENT AND DETECTION OF CANCER | April 2010 | January 2012 | Allow | 21 | 1 | 1 | No | No |
| 12725955 | TREATING NEOPLASMS WITH NEUROTOXIN | March 2010 | October 2012 | Allow | 31 | 1 | 1 | No | No |
| 12718821 | BPC-1: A SECRETED BRAIN-SPECIFIC PROTEIN EXPRESSED AND SECRETED BY PROSTATE AND BLADDER CANCER CELLS | March 2010 | April 2011 | Allow | 14 | 1 | 1 | No | No |
| 12597735 | S100A9 INTERACTION SCREENING METHOD | March 2010 | June 2014 | Allow | 56 | 2 | 1 | No | No |
| 12596196 | Biomarkers for Follicular Thyroid Carcinoma and Methods of Use | March 2010 | March 2013 | Allow | 41 | 1 | 1 | No | No |
| 12523514 | GENE POLYMORPHISMS PREDICTIVE FOR DUAL TKI THERAPY | February 2010 | November 2012 | Allow | 40 | 1 | 1 | No | No |
| 12709848 | METHOD FOR PREPARATION OF SINGLE CHAIN ANTIBODIES | February 2010 | December 2011 | Allow | 22 | 2 | 1 | No | No |
| 12697700 | IN VITRO TUMOR ANGIOGENESIS MODEL | February 2010 | May 2012 | Allow | 27 | 1 | 1 | No | No |
| 12630458 | BIOMARKERS FOR EARLY DETECTION OF OVARIAN CANCER | December 2009 | August 2012 | Allow | 32 | 1 | 1 | Yes | No |
| 12627335 | ANTIBODIES THAT BIND TO EPHA2 AND METHODS OF USE THEREOF | November 2009 | February 2012 | Allow | 26 | 0 | 0 | No | No |
| 12592540 | TREATING NEOPLASMS WITH NEUROTOXIN | November 2009 | August 2012 | Allow | 33 | 1 | 0 | No | No |
| 12526681 | REGULATION OF EXPRESSION OF PI3KBETA PROTEIN IN TUMORS | November 2009 | September 2011 | Allow | 26 | 1 | 1 | No | No |
| 12589647 | ISOLATED NUCLEIC ACID MOLECULES ENCODING CANCER ASSOCIATED ANTIGENS, THE ANTIGENS PER SE, AND USES THEREOF | October 2009 | August 2011 | Allow | 21 | 1 | 0 | No | No |
| 12605185 | GENE ENCODING LABYRINTHIN, A MARKER FOR CANCER | October 2009 | December 2011 | Allow | 26 | 2 | 1 | Yes | Yes |
| 12587870 | PROTEIN INVOLVED IN OVARIAN CANCER | October 2009 | June 2012 | Allow | 32 | 1 | 1 | No | No |
| 12595678 | AUTOIMMUNE REGULATION OF PROSTATE CANCER BY ANNEXIN A3 | October 2009 | October 2012 | Allow | 36 | 2 | 1 | Yes | No |
| 12575092 | NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCERS AND USES THEREOF | October 2009 | December 2010 | Allow | 14 | 1 | 0 | No | No |
| 12575164 | NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCERS AND USES THEREOF | October 2009 | February 2011 | Allow | 16 | 1 | 1 | No | No |
| 12568134 | NOVEL MHC CLASS II RESTRICTED T CELL EPITOPES FROM THE CANCER ANTIGEN, NY ESO-1 | September 2009 | January 2014 | Allow | 52 | 3 | 1 | No | No |
| 12559634 | PERINUCLEOLAR COMPARTMENT AS A CANCER MARKER | September 2009 | April 2012 | Allow | 31 | 1 | 1 | No | No |
| 12552746 | USE OF A TRUNCATED EIF-5A1 POLYNUCLEOTIDE TO INDUCE APOPTOSIS IN CANCER CELLS | September 2009 | October 2012 | Allow | 37 | 1 | 1 | No | No |
| 12523517 | POLYMORPHISMS IN THE EGFR PATHWAY AS MARKERS FOR CANCER TREATMENT | August 2009 | May 2012 | Allow | 34 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HALVORSON, MARK.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 29.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HALVORSON, MARK works in Art Unit 1646 and has examined 184 patent applications in our dataset. With an allowance rate of 88.6%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 37 months.
Examiner HALVORSON, MARK's allowance rate of 88.6% places them in the 66% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by HALVORSON, MARK receive 2.09 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HALVORSON, MARK is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +11.9% benefit to allowance rate for applications examined by HALVORSON, MARK. This interview benefit is in the 51% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 29.5% of applications are subsequently allowed. This success rate is in the 47% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 48.7% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 93.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 61.9% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 21.7% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.7% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.